111 (NASDAQ:YI) Earns “Sell (D-)” Rating from Weiss Ratings

111 (NASDAQ:YI)‘s stock had its “sell (d-)” rating restated by equities researchers at Weiss Ratings in a research note issued on Thursday,Weiss Ratings reports.

111 Trading Up 4.3%

Shares of NASDAQ YI opened at $6.57 on Thursday. 111 has a 1-year low of $4.14 and a 1-year high of $11.90. The company has a 50-day moving average of $7.38 and a two-hundred day moving average of $7.78. The company has a market cap of $56.76 million, a PE ratio of -10.27 and a beta of 0.43.

111 (NASDAQ:YI) last announced its quarterly earnings data on Thursday, June 19th. The company reported ($0.20) EPS for the quarter. The business had revenue of $486.35 million during the quarter.

Institutional Investors Weigh In On 111

Several large investors have recently modified their holdings of YI. Deuterium Capital Management LLC bought a new position in 111 during the 1st quarter worth about $81,000. Connor Clark & Lunn Investment Management Ltd. acquired a new position in shares of 111 during the first quarter worth about $92,000. Finally, JPMorgan Chase & Co. boosted its position in shares of 111 by 43,619.9% during the fourth quarter. JPMorgan Chase & Co. now owns 306,039 shares of the company’s stock worth $191,000 after buying an additional 305,339 shares during the period. 21.32% of the stock is currently owned by institutional investors.

111 Company Profile

111, Inc engages in the provision of pharmaceutical products and medical services through online retail pharmacy and indirectly through offline pharmacy network. It operates through the B2C and B2B segments. The B2C segment engages in the sale of pharmaceutical and other health and wellness products directly to consumers through 1 Drugstore and its offline pharmacies.